Related Articles
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines
Comparison of the efficacy of icotinib in patients with non‑small‑cell lung cancer according to the type of epidermal growth factor receptor mutation
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib
Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR‑T790M mutant lung cancer
In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines